Fluid Biomarkers in Alzheimer Disease
Fluid Biomarkers in Alzheimer Disease
复制标题
DOI：
10.1101/cshperspect.a006221
复制
发表时间：
2012-09-01
影响因子：
5.4
通讯作者：
Fagan, Anne M.
中科院分区：
文献类型：
--
作者：
Blennow, Kaj;Zetterberg, Henrik;Fagan, Anne M.
近年来，阿尔茨海默病（Alzheimer disease，AD）的研究进展使人们对AD的分子发病机制有了更深入的了解。这些知识已被转化为具有假定疾病改善作用的新候选药物，目前正在临床试验中进行测试。有效治疗的前景创造了对能够在痴呆前期检测AD的生物标志物的巨大需求，因为只有在神经变性不太严重的情况下，药物才可能有效。在本章中，脑脊液（CSF）和血浆生物标志物进行了审查。核心CSF生物标志物总tau（T-tau）、磷酸化tau（P-tau）和42个氨基酸形式的β-淀粉样蛋白（A β 42）反映了AD病理学，并且在轻度认知障碍病例中具有诊断AD伴痴呆和前驱AD的高诊断准确性。本章还概述了使用CSF生物标志物识别和监测新药候选药物作用机制的基本原理。
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new drug candidates with putative disease-modifying effects, which are now being tested in clinical trials. The promise of effective therapy has created a great need for biomarkers able to detect AD in the predementia phase, because drugs will probably be effective only if neurodegeneration is not too advanced. In this chapter, cerebrospinal fluid (CSF) and plasma biomarkers are reviewed. The core CSF biomarkers total tau (T-tau), phosphorylated tau (P-tau) and the 42 amino acid form of beta-amyloid (A beta 42) reflect AD pathology, and have high diagnostic accuracy to diagnose AD with dementia and prodromal AD in mild cognitive impairment cases. The rationale for the use of CSF biomarkers to identify and monitor the mechanism of action of new drug candidates is also outlined in this chapter.